OliX Pharmaceuticals Announces Completion of Enrollment in Phase II Clinical Trial of OLX101A in Patients with Hypertrophic Scars

By
mladbrook
-
0
174
OliX Pharmaceuticals, Inc. announced the completion of patient enrollment in the Phase IIa clinical trial of OLX101A, an investigational therapeutic program for the treatment of hypertrophic scar.
[OliX Pharmaceuticals, Inc. (Business Wire)]
Press Release